Presentation of Research Results on New Drug Pipeline Including Cancer Stem Cell-Targeting Anticancer Agents
Idience, a new drug development specialist company under Ildong Pharmaceutical Group, announced on the 27th that it will present research results on newly added anticancer drug candidates in its new drug pipeline at the American Association for Cancer Research (AACR) conference held in Chicago, USA, from the 25th to the 30th of next month.
The new drug candidates to be disclosed this time include four types: ▲ cancer stem cell-targeting anticancer agent 'ID12023' ▲ KRAS mutant non-small cell lung cancer, pancreatic cancer, and colorectal cancer-targeting anticancer agent 'ID12241' ▲ refractory prostate cancer treatment agent 'ID11916' ▲ antibody-drug conjugate (ADC) loaded with PARP1 inhibitor 'ID12401'.
The cancer stem cell-targeting anticancer agent 'ID12023', whose related research results will be disclosed through an oral presentation at the 'microRNAs and Other noncoding RNAs' session of the AACR conference on the 27th of next month, is a new drug candidate that normalizes the expression of 'microRNA' within cancer cells to treat intractable malignant tumors.
Research results showed that ID12023 effectively regulates major markers of cancer stem cells such as OCT4, SOX2, and MYC, and demonstrated tumor suppression effects in vitro and in vivo tumor models, along with excellent pharmacokinetic properties such as bioavailability (over 30%) and half-life (about 3 hours).
On the 29th, the fifth day of the conference, research results on promising anticancer drug candidates ▲ ID12241 ▲ ID11916 ▲ ID12401 will be presented in poster format.
ID12241 is a pan-KRAS inhibitor that shows anticancer activity in various KRAS mutant cancers including G12C, G12D, and G12V. The research demonstrated excellent target selectivity and tumor suppression effects, proving its potential as a universal treatment for KRAS mutant cancers.
ID11916 is a candidate drug for refractory prostate cancer treatment. It has a dual regulatory mechanism of androgen receptor inhibition and PKG activation. Nonclinical studies confirmed superior anticancer effects compared to competing drugs targeting prostate cancer, breast cancer, and androgen receptor inhibitor-resistant prostate cancer.
ID12401 is an antibody-drug conjugate (ADC) utilizing a PARP1 inhibitor as the payload, representing a next-generation anticancer platform that can overcome resistance and toxicity issues seen in existing chemotherapy and ADCs. Strong anticancer effects were confirmed through in vitro and in vivo tumor model studies. Safety was demonstrated with no hematologic toxicity or weight loss side effects observed.
Lee Won-sik, CEO of Idience, stated, "The selection of our anticancer drug pipeline for multiple oral and poster presentations at a prestigious cancer conference is a great opportunity to showcase Idience's research and development capabilities as well as the value and competitiveness of these candidate substances."
He added, "Along with progressing clinical development projects for our promising new drug pipeline and anticancer candidates, we plan to simultaneously pursue commercialization discussions through business partner discovery and license-out initiatives."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
